FDA Warns of Undeclared PDE5 Inhibitors in OTC Male Enhancement Products

FDA Warns of Undeclared PDE5 Inhibitors in OTC Male Enhancement Products

The U.S. Food and Drug Administration issued an updated safety communication on June 12, 2024, stating that multiple dietary supplements marketed for male sexual enhancement contain undeclared PDE5 inhibitors. The agency identified hidden sildenafil, tadalafil, and related analogs not listed on product labels. [1]

The findings expand on previous FDA alerts regarding adulterated sexual enhancement supplements. Agency data indicate these products continue to appear in online and retail channels despite repeated notifications. [2][4]

What this means

The updated communication indicates that unapproved prescription-strength PDE5 inhibitors are present in products sold as dietary supplements. FDA documents associate these ingredients with physiological effects on blood pressure and vascular function, particularly when combined with nitrates. The persistence of such adulteration points to ongoing challenges in monitoring the supplement marketplace.

Undeclared Ingredients Detected

The FDA reported that multiple supplements contain hidden sildenafil, tadalafil, or structural analogs that are not declared on their labels. [1] These compounds are active pharmaceutical ingredients typically found in FDA-approved prescription medications for erectile dysfunction.

Documented Health Risks

FDA safety information links the undeclared ingredients to potential adverse events that include severe hypotension, especially in individuals using nitrates for cardiovascular conditions. Other effects associated with these ingredients include headache, flushing, back pain, and priapism. [2][3]

Regulatory Context

The June 12, 2024 safety communication represents an expansion of prior FDA alerts on tainted sexual enhancement products. [1] The agency maintains an ongoing catalog of enforcement actions and examples of hidden ingredients under its medication health fraud monitoring. [3]

National Library of Medicine consumer health feeds have referenced the FDA alerts in updates on dietary supplement safety. [4]

FDA Communications on Adverse Event Reporting

The FDA has described pathways for reporting adverse events linked to these products through its MedWatch program and has outlined information for healthcare providers in associated consumer updates. [2]

Limitations

FDA communications reflect only tested products and cannot encompass every adulterated item on the market; data is primarily US-centric; long-term population-level adverse event rates linked specifically to these supplements remain under-reported.